骨质疏松性椎体骨折患者血清破骨细胞生成抑制因子和破骨细胞分化因子的表达及意义
|
摘要
目的探讨骨质疏松性椎体骨折患者血清破骨细胞生成抑制因子(osteoclast suppressor,OCIF)和破骨细胞分化因子(osteoclast differentiation factor,ODF)的表达及意义。方法选择衢州市人民医院2013年1月—2016年12月符合标准的骨质疏松性椎体骨折患者70例为骨质疏松组,非骨质疏松性椎体骨折患者70例为对照组。采用双抗体夹心酶联免疫吸附实验(Double antibody sandwich enzyme-linked immunosorbent assay,ELISA)法测定血清OCIF和ODF水平。采用双能X线骨密度仪测量腰椎正位总体L1～4骨密度及左侧股骨颈骨密度。采用SPSS20. 0统计软件对数据进行分析。结果骨质疏松组血清OCIF和ODF水平均高于对照组(均P <0. 05)。骨质疏松组腰椎正位骨密度和股骨颈骨密度均低于对照组(均P <0. 05)。骨质疏松患者血清OCIF、ODF水平与腰椎正位骨密度、股骨颈骨密度均呈负相关(均P <0. 05)。骨质疏松患者血清OCIF、ODF水平与骨折程度无显著相关性(均P> 0. 05)。结论骨质疏松性椎体骨折患者血清OCIF、ODF水平升高,血清OCIF、ODF水平与骨质疏松性椎体骨折患者的骨密度关系密切,与骨折的严重程度关系不大。
Objective To investigate the expression and significance of osteoclastogenesis inhibitory factor( OCIF) and osteoclast differentiation factor( ODF) in patients with osteoporotic vertebral fractures. Methods Total 70 cases of osteoporotic vertebral fractures were selected as osteoporosis group,and 70 cases of non-osteoporotic vertebral fractures were selected as control group in Quzhou People' s Hospital from January 2013 to December 2016. The serum levels of OCIF and ODF were tested by double antibody sandwich enzyme-linked immunosorbent assay( ELISA). Dual-energy X-ray absorptiometry was used to measure the total L1-4bone mineral density in the lumbar spine and left femoral neck. The SPSS20. 0 software was used to analyze the data. Results The levels of serum OCIF and ODF in the osteoporosis group were higher than those in the control group( all P < 0. 05). The lumbar spine bone mineral density and femoral neck bone mineral density in the osteoporosis group were lower than those in the control group( all P < 0. 05). The serum OCIF,ODF in the osteoporosis group were negatively correlated with lumbar spine bone mineral density and femoral neck bone mineral density( all P < 0. 05). The serum OCIF and ODF levels in patients with osteoporosis had no significant correlation with the degree of fracture( all P > 0. 05). Conclusion The serum OCIF and ODF levels increase obviously in the patients with osteoporotic vertebral fractures,and closely related to the bone mineral density,and not with the severity of the fracture.
Objective To investigate the expression and significance of osteoclastogenesis inhibitory factor( OCIF) and osteoclast differentiation factor( ODF) in patients with osteoporotic vertebral fractures. Methods Total 70 cases of osteoporotic vertebral fractures were selected as osteoporosis group,and 70 cases of non-osteoporotic vertebral fractures were selected as control group in Quzhou People' s Hospital from January 2013 to December 2016. The serum levels of OCIF and ODF were tested by double antibody sandwich enzyme-linked immunosorbent assay( ELISA). Dual-energy X-ray absorptiometry was used to measure the total L1-4bone mineral density in the lumbar spine and left femoral neck. The SPSS20. 0 software was used to analyze the data. Results The levels of serum OCIF and ODF in the osteoporosis group were higher than those in the control group( all P < 0. 05). The lumbar spine bone mineral density and femoral neck bone mineral density in the osteoporosis group were lower than those in the control group( all P < 0. 05). The serum OCIF,ODF in the osteoporosis group were negatively correlated with lumbar spine bone mineral density and femoral neck bone mineral density( all P < 0. 05). The serum OCIF and ODF levels in patients with osteoporosis had no significant correlation with the degree of fracture( all P > 0. 05). Conclusion The serum OCIF and ODF levels increase obviously in the patients with osteoporotic vertebral fractures,and closely related to the bone mineral density,and not with the severity of the fracture.
引文
[1] ABETEL G,FERRARI S. Osteoporotic fractures:not only in females[J]. Rev Med Suisse,2014,10(424):767-768.
[2] POIANA C,CARSOTE M,RADOI V,et al. Prevalent osteoporotic fractures in 622 obese and non-obese menopausal women[J]. J Med Life,2015,8(4):462-466.
[3] AKIYAMA T,MIYAMOTO Y,YOSHIMURA K,et al. Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-αand interleukin-1βbut suppresses that by interleukin-17A:importance of proteolytic degradation of osteoprotegerin by lysine gingipain[J]. J Biol Chem,2014,289(22):15621-15630.
[4] UCHINO K,OKAMOTO K,SAKAI E,et al. Dual effects of liquiritigenin on the proliferation of bone cells:promotion of osteoblast differentiation and Inhibition of osteoclast differentiation[J]. Phytother Res,2015,29(11):1714-1721.
[5]缪寿亮,周湘兰,郑祥武.胸腰椎压缩性骨折压缩程度评估方法比较[J].中国法医学杂志,2016,31(2):171-173.
[6] WONG A K,CAWTHON P M,PETERS K W,et al. Bone-muscle indices as risk factors for fractures in men:the Osteoporotic Fractures in Men(Mr OS)Study[J]. J Musculoskelet Neuronal Interact,2014,14(3):246-254.
[7] MATTIE R,LAIMI K,YU S,et al. Comparing percutaneous vertebroplasty and conservative therapy for treating osteoporotic compression fractures in the thoracic and lumbar spine:a systematic review and meta-analysis[J]. J Bone Joint Surg Am,2016,98(12):1041-1051.
[8] KUCHAY M S,BANSAL B,MITHAL A. Pitfalls in interpreting interventional studies for osteoporosis[J]. Clin Cases Miner Bone Metab,2017,14(3):329-331.
[9] GOYAL L,GOYAL T,GUPTA N D. Osteoporosis and Periodontitis in Postmenopausal Women:A Systematic Review[J]. J Midlife Health,2017,8(4):151-158.
[10] TOM-BERMEJO F,PIERA A R,ALVAREZ L. Osteoporosis and the management of spinal degenerative disease(Ⅱ)[J]. Arch Bone Jt Surg,2017,5(6):363-374.
[11] YOON B H,LEE J K,CHOI D S,et al. Prevalence and associated risk factors of sarcopenia in female patients with osteoporotic fracture[J]. J Bone Metab,2018,25(1):59-62.
[12] GOODE S C,BESHEARS J L,GOODE R D,et al. Putting the brakes on breaks:osteoporosis screening and fracture prevention[J]. Geriatr Orthop Surg Rehabil,2017,8(4):238-243.
[13] JANKOVIC'T,SVORCAN J Z,BOSKOVI C'K. Verification of osteoporotic vertebral fractures caused by glucocorticoids[J]. Med Pregl,2014,67(3-4):118-122.
[14] GAO L H,LI S S,SHAO C,et al. BMP7 gene polymorphisms are not associated with bone mineral density or osteoporoticfractures in postmenopausal Chinese women[J]. Acta Pharmacol Sin,2016,37(8):1076-1082.
[15]谭云昌.血清破骨细胞分化因子及生成抑制因子测定在前列腺癌骨转移诊断中的价值[J].中国现代医学杂志,2014,24(1):37-40.
[16]陈奎,陈俊,胡永文.前列腺癌骨转移患者血清ODF、OCIF含量及临床价值评估[J].海南医学院学报,2015,21(12):1690-1692,1696.
[17] SASSO G R,FLORENCIO-SILVA R,SIMES R S,et al. Elevated serum osteoprotegerin levels in women:friend or foe?[J]. Rev Assoc Med Bras(1992),2015,61(6):524-529.
[18] LIU W,ZHANG X. Receptor activator of nuclear factor-κB ligand(RANKL)/RANK/osteoprotegerin system in bone and other tissues(review)[J]. Mol Med Rep,2015,11(5):3212-3218.
[19] TYROVOLA J B. The“Mechanostat Theory”of Frost and the OPG/RANKL/RANK System[J]. J Cell Biochem,2015,116(12):2724-2729.
[20]胡海澜,凌龙,何敏辉,等.绝经后不同骨关节退行性疾病与骨质疏松程度的相关性研究[J].中国骨质疏松杂志,2017,23(5):623-626.
[2] POIANA C,CARSOTE M,RADOI V,et al. Prevalent osteoporotic fractures in 622 obese and non-obese menopausal women[J]. J Med Life,2015,8(4):462-466.
[3] AKIYAMA T,MIYAMOTO Y,YOSHIMURA K,et al. Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-αand interleukin-1βbut suppresses that by interleukin-17A:importance of proteolytic degradation of osteoprotegerin by lysine gingipain[J]. J Biol Chem,2014,289(22):15621-15630.
[4] UCHINO K,OKAMOTO K,SAKAI E,et al. Dual effects of liquiritigenin on the proliferation of bone cells:promotion of osteoblast differentiation and Inhibition of osteoclast differentiation[J]. Phytother Res,2015,29(11):1714-1721.
[5]缪寿亮,周湘兰,郑祥武.胸腰椎压缩性骨折压缩程度评估方法比较[J].中国法医学杂志,2016,31(2):171-173.
[6] WONG A K,CAWTHON P M,PETERS K W,et al. Bone-muscle indices as risk factors for fractures in men:the Osteoporotic Fractures in Men(Mr OS)Study[J]. J Musculoskelet Neuronal Interact,2014,14(3):246-254.
[7] MATTIE R,LAIMI K,YU S,et al. Comparing percutaneous vertebroplasty and conservative therapy for treating osteoporotic compression fractures in the thoracic and lumbar spine:a systematic review and meta-analysis[J]. J Bone Joint Surg Am,2016,98(12):1041-1051.
[8] KUCHAY M S,BANSAL B,MITHAL A. Pitfalls in interpreting interventional studies for osteoporosis[J]. Clin Cases Miner Bone Metab,2017,14(3):329-331.
[9] GOYAL L,GOYAL T,GUPTA N D. Osteoporosis and Periodontitis in Postmenopausal Women:A Systematic Review[J]. J Midlife Health,2017,8(4):151-158.
[10] TOM-BERMEJO F,PIERA A R,ALVAREZ L. Osteoporosis and the management of spinal degenerative disease(Ⅱ)[J]. Arch Bone Jt Surg,2017,5(6):363-374.
[11] YOON B H,LEE J K,CHOI D S,et al. Prevalence and associated risk factors of sarcopenia in female patients with osteoporotic fracture[J]. J Bone Metab,2018,25(1):59-62.
[12] GOODE S C,BESHEARS J L,GOODE R D,et al. Putting the brakes on breaks:osteoporosis screening and fracture prevention[J]. Geriatr Orthop Surg Rehabil,2017,8(4):238-243.
[13] JANKOVIC'T,SVORCAN J Z,BOSKOVI C'K. Verification of osteoporotic vertebral fractures caused by glucocorticoids[J]. Med Pregl,2014,67(3-4):118-122.
[14] GAO L H,LI S S,SHAO C,et al. BMP7 gene polymorphisms are not associated with bone mineral density or osteoporoticfractures in postmenopausal Chinese women[J]. Acta Pharmacol Sin,2016,37(8):1076-1082.
[15]谭云昌.血清破骨细胞分化因子及生成抑制因子测定在前列腺癌骨转移诊断中的价值[J].中国现代医学杂志,2014,24(1):37-40.
[16]陈奎,陈俊,胡永文.前列腺癌骨转移患者血清ODF、OCIF含量及临床价值评估[J].海南医学院学报,2015,21(12):1690-1692,1696.
[17] SASSO G R,FLORENCIO-SILVA R,SIMES R S,et al. Elevated serum osteoprotegerin levels in women:friend or foe?[J]. Rev Assoc Med Bras(1992),2015,61(6):524-529.
[18] LIU W,ZHANG X. Receptor activator of nuclear factor-κB ligand(RANKL)/RANK/osteoprotegerin system in bone and other tissues(review)[J]. Mol Med Rep,2015,11(5):3212-3218.
[19] TYROVOLA J B. The“Mechanostat Theory”of Frost and the OPG/RANKL/RANK System[J]. J Cell Biochem,2015,116(12):2724-2729.
[20]胡海澜,凌龙,何敏辉,等.绝经后不同骨关节退行性疾病与骨质疏松程度的相关性研究[J].中国骨质疏松杂志,2017,23(5):623-626.